Previous therapy with any PD- or PD-L inhibitor including durvalumab or anti-CTLA (including tremelimumab) for any malignancy.
Previous treatment with a CTLA-, PD-, or PD-L inhibitor, including prior treatment with either durvalumab or tremelimumab
Prior systemic anti-cancer therapy of any kind for RCC, including but not limited to any approved agent or any previous treatment with a PD or PD-L inhibitor including durvalumab; no previous treatment with immunotherapy for any malignancy including cytokine, anti-tumor vaccine, T-cell activator, co-stimulator or immune checkpoint inhibitor
Any previous treatment with a PD or PD-L inhibitor, including durvalumab or an anti-CTLA inhibitor including tremelimumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD- or PD-L inhibitor, including but not limited to: nivolumab, atezolizumab, pembrolizumab, or durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab or an anti-CTLA, including tremelimumab.
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab, and therapeutic anticancer vaccine
Previous treatment with Anti-CTLA- including tremelimumab or PD/PD-L inhibitor, including durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab or an anti-CTLA, including tremelimumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab or an anti-CTLA, including tremelimumab
Any previous treatment with adoptive T cells therapy, a PD or PDL inhibitor, including durvalumab or any anti-CTLA therapy, including tremelimumab.
Any previous treatment with a PD or PD-L inhibitor, including durvalumab or an anti-CTLA, including tremelimumab
History of discontinuation of any previous treatment with PARP inhibitors, including olaparib, or a PD- or PD-L inhibitor, including durvalumab or anti-CTLA antibody, including tremelimumab due to toxicity
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab or an anti-cytotoxic T-lymphocyte-associated protein  (CTLA), including tremelimumab
Any previous treatment with a PD or PD-L inhibitor, including MEDI
Previous therapy with any PD or PD-L inhibitor (including durvalumab) for any malignancy.
Prior treatment with an anti-CTLA-, including tremelimumab PD- or PD-L inhibitor, including durvalumab
History of hypersensitivity to durvalumab or tremelimumab or any CTLA, PD, or PDL- inhibitor
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD- or PD-L inhibitor, including durvalumab
Any previous treatment with a PD- or PD-L inhibitor, including durvalumab or an anti-CTLA-, including tremelimumab
Any previous treatment with an anti-CTLA, including tremelimumab or any previous treatment with a PD or PDL inhibitor
Any previous treatment with a PD- or PD-L inhibitor, including durvalumab or any anti-CTLA, including tremelimumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab or an anti-CTLA, including tremelimumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD or PD-L inhibitor, including durvalumab
Any previous treatment with a PD- or PD-L inhibitor, including durvalumab or an anti- CTLA-, including tremelimumab